CN104962575A - 牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法 - Google Patents
牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法 Download PDFInfo
- Publication number
- CN104962575A CN104962575A CN201510358543.5A CN201510358543A CN104962575A CN 104962575 A CN104962575 A CN 104962575A CN 201510358543 A CN201510358543 A CN 201510358543A CN 104962575 A CN104962575 A CN 104962575A
- Authority
- CN
- China
- Prior art keywords
- porphyromonas gingivalis
- rgpa
- gene
- mutant strain
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003209 gene knockout Methods 0.000 title claims abstract description 22
- 101100007556 Porphyromonas gingivalis rgpA gene Proteins 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 239000012634 fragment Substances 0.000 claims abstract description 29
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 25
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 22
- 241000605862 Porphyromonas gingivalis Species 0.000 claims abstract description 18
- 230000006801 homologous recombination Effects 0.000 claims abstract description 18
- 238000002744 homologous recombination Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000012216 screening Methods 0.000 claims abstract description 12
- 230000003321 amplification Effects 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- 229960003276 erythromycin Drugs 0.000 claims description 11
- 230000009466 transformation Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 abstract description 3
- 230000006798 recombination Effects 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract description 2
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 abstract 3
- 229940098008 erythrocin Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 239000006161 blood agar Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 101100445523 Bacteroides fragilis ermF gene Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108091020100 Gingipain Cysteine Endopeptidases Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 108010022355 Fibroins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000006781 columbia blood agar Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 101100380241 Caenorhabditis elegans arx-2 gene Proteins 0.000 description 1
- 241000201350 Harveya Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 101100335159 Porphyromonas gingivalis (strain ATCC 33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 2561) fmt gene Proteins 0.000 description 1
- 241000191023 Rhodobacter capsulatus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101150092805 actc1 gene Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 101150076810 erm gene Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 101150065098 glnG gene Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 101150012415 ntrC gene Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 101150084818 prtH gene Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 229940082924 vitamin k 0.5 mg Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,本发明涉及口腔医学领域。所述方法包括如下步骤:扩增牙龈卟啉单胞菌RgpA基因的上、下游同源臂;扩增红霉素抗性基因片段;构建两端为所述RgpA基因的上、下游同源臂,中间为红霉素抗性基因片段的同源重组片段;将同源重组片段转化入牙龈卟啉单胞菌内,进行同源重组,采用红霉素抗性平板筛选,获得牙龈卟啉单胞菌RgpA基因敲除突变株。本发明牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,操作简便灵活,无需繁琐的酶切连接和筛选,对突变位点的选择无特异性要求,重组效率高。
Description
技术领域
本发明涉及口腔医学领域,具体涉及牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法。
背景技术
牙龈卟啉单胞菌(Porphyromonas gingivalis,缩写为P.g)是一种非酵解糖的革兰氏阴性厌氧球杆菌,是研究广泛且证据充足的重要牙周致病菌之一。国外有学者研究发现37%的0~18岁个体中均可检测到P.g。牙龈素(Gingipains)是P.g在细胞内合成并分泌到细胞外的一种胰蛋白酶样半胱氨酸蛋白酶,在其致病性中起着重要作用。它包括具有与赖氨酸残基特异结合活性的牙龈素蛋白酶K(gingipainK,Kgp)和与精氨酸残基特异结合活性的牙龈素蛋白酶R(gingipainR,Rgp)。其中,Rgp包括RgpA和RgpB两种存在形式。为了研究牙龈卟啉单胞菌的致病机制、寻找治疗方法,需要研究上述蛋白酶的相关功能。通常采用敲除目的基因的方法,来研究牙龈蛋白酶的功能。但是,采用常规方法敲除牙龈蛋白酶,需要进行大量的筛选工作,工作效率较低。
发明内容
本发明的目的是提供牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,该方法简单高效。
本发明的目的采用如下技术方案实现。
牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,包括如下步骤:
(1)扩增牙龈卟啉单胞菌RgpA基因的上、下游同源臂;
(2)扩增红霉素抗性基因片段;
(3)构建两端为所述RgpA基因的上、下游同源臂,中间为红霉素抗性基因片段的同源重组片段;
(4)将同源重组片段转化入牙龈卟啉单胞菌内,进行同源重组,采用红霉素抗性平板筛选,获得牙龈卟啉单胞菌RgpA基因敲除突变株。
在本发明中,所述上游同源臂的序列如SEQ ID NO:1所示,所述下游同源臂的序列如SEQID NO:2所示。
在本发明中,步骤(4)中采用电转化方法将同源重组片段转化入牙龈卟啉单胞菌内,电击条件为:电压为2.5kV、电击时间为5ms。
在本发明中,以牙龈卟啉单胞菌的基因组DNA为模板,以upF和upR为引物,扩增RgpA基因的上游同源臂;以牙龈卟啉单胞菌的基因组DNA为模板,以downF和downR为引物,扩增RgpA基因的下游同源臂;所述upF的序列为:ccgaattcGGATACGGGTTCGTCTATGTAGCGGCGGAAAAATGC:所述upR的序列为:CGGAAGCTATCGGGGGTACCGTTTTTCATTTTGATG所述downF的序列为:CTAGAGTCGACCTGCAGTTCTGTCTTGGACTCGGAG所述downR的序列为:aaggatccTATCTATCTCATGCCGGAGGCGGAAGGTGGTAACTC。
有益效果:本发明牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,操作简便灵活,无需繁琐的酶切连接和筛选,对突变位点的选择无特异性要求,重组效率高。
附图说明
图1.制备牙龈卟啉单胞菌RgpA基因敲除突变株,原理图,WT:野生型P.g。RgpA-:RgpA基因突变型P.g。PGN_1969和PGN_19671分别为RgpA基因的上、下游基因。
图2.牙龈卟啉单胞菌RgpA基因敲除突变株构建过程中的电泳图。(A)P.g基因组和抗性基因的扩增电泳图,其中泳道1,2:上游同源臂(1kb);3,4:抗性基因erm(2.2kb);5,6:下游同源臂(1kb)。(B)重组片段up_erm_down的构建电泳图,1,2:overlap PCR的产物up_erm_down(4.3kb)。(C)质粒pPHU281_up_erm_down的酶切验证电泳图。1:质粒的EcoRⅠ酶切产物(6.9kb,4.3kb);2:质粒的SacⅠ酶切产物(11.2kb)。(D)RgpA基因敲除突变株的正向验证电泳图,其中1-4:突变株;5:野生株;6:质粒pPHU281_up_erm_down(阳性对照)。(E)RgpA基因敲除突变株的反向验证电泳图,1-4:突变株;5:野生株;6.质粒pPHU281_up_erm_down(阳性对照)。
图3.含有红霉素的哥伦比亚血琼脂平板培养照片。
具体实施方式
采用下面的方法制备牙龈卟啉单胞菌RgpA基因敲除突变株,原理如图1所示。
1.质粒pPHU281_up_erm_down的制备
(1)RgpA基因上、下游同源臂的扩增和纯化
选择RgpA基因编码区起始密码子开始向上游818bp的序列作为上游同源臂(序列如SEQID NO:1所示),RgpA编码区终止密码子开始向下游686bp的序列作为下游同源臂(序列如SEQ ID NO:2所示)。
根据P.gATCC33277株(野生株)的RgpA基因序列(GenBank:6330747),使用Oligo6软件设计扩增RgpA基因上、下游同源臂的引物,使用BLAST对引物进行同源性分析后,由南京金斯瑞生物科技有限公司合成。
其中,扩增上游同源臂的引物包括upF和upR,具体序列如下:
upF(SEQ ID NO:3):ccgaattcGGATACGGGTTCGTCTATGTAGCGGCGGAAAAATGC,
upR(SEQ ID NO:4):CGGAAGCTATCGGGGGTACCGTTTTTCATTTTGATG。
以P.gATCC33277株基因组DNA为模板,以upF、upR为引物扩增,扩增RgpA基因上游同源臂。PCR体系(相关试剂购自thermo,USA)如下:
PCR反应条件:94℃5min;94℃30s,60℃30s,72℃2min,35cylce;72℃10min。
产物经1.0%琼脂糖凝胶电泳检测,并回收上游同源臂片段up,大小约为1.1kb。
下游同源臂的扩增引物为downF和downR。仅改变引物,采用上述相同反应体系和反应条件扩增下游同源臂。扩增引物的具体序列如下:
downF(SEQ ID NO:7):CTAGAGTCGACCTGCAGTTCTGTCTTGGACTCGGAG,
downR(SEQ ID NO:8):aaggatccTATCTATCTCATGCCGGAGGCGGAAGGTGGTAACTC。产物经1.0%琼脂糖凝胶电泳检测,并回收上游同源臂片段down,大小约为1kb。RgpA基因上、下游同源臂PCR扩增产物电泳图如图2(A)所示。
(2)ermF-ermAM抗性基因的扩增和纯化
根据质粒pVA2198(Hansel M.fletcher,Harveya.Schenkein,Roderick M.Morgan,et al.Virulence of a Porphyromonas gingivalis W83mutant defective in the prtH gene.Infection andimmunity.1995,63:1521-1528.)上ermF-ermAM基因(红霉素抗性基因,GenBank:AF219231.1)序列,使用Oligo6软件设计引物ermF和ermR,以质粒pVA2198为模板,扩增ermF-ermAM抗性基因。引物由南京金斯瑞生物科技有限公司合成。
其中,ermF和ermR的序列如下:
ermF序列(SEQ ID NO:5):CATCAAAATGAAAAACGGTACCCCCGATAGCTTCCG,
ermR序列(SEQ ID NO:6):CTCCGAGTCCAAGACAGAACTGCAGGTCGACTCTAG。
PCR反应体系参照标题(1)中,不同之处在于模板为质粒pVA2198,引物为ermF和ermR。PCR反应条件:94℃5min;94℃30s,57℃30s,72℃4min30s,35cylce;72℃10min。产物经1.0%琼脂糖凝胶电泳检测,结果如图2(A)所示,回收目的条带中的产物,获得ermF-ermAM抗性基因片段(记为erm,2.2kb)
(3)overlap PCR扩增同源重组片段
①重叠延伸反应
该反应中片段up、erm、down的摩尔数比为1:1:1,三条片段互为模板和引物,延伸获得长度为4.3kb的同源重组片段。
反应体系如下:
反应程序:94℃5min预变性;94℃30s,60℃30s,72℃4min,8个循环;72℃延伸10min。
②扩增反应
在重叠延伸反应产物(25μl)中加入外侧引物upF(10μM,带有EcoR I位点)和downR(10μM,带有BamH I位点)各1.5ul,立即开始扩增反应,除循环数设置为30个循环,余PCR反应程序同重叠延伸反应。最终获得同源重组片段A(SEQ ID NO:9),记为up_erm_down。同源重组片段A自5’至3’端依次为上游同源臂up、ermF-ermAM抗性基因片段erm和下游同源臂down。PCR产物采用2%凝胶电泳检测,结果如图2(B)。所示。回收目的条带。
(4)质粒pGT_up_erm_dowm的构建及鉴定
对上述获得的长片段up_erm_down两端进行加A反应,反应产物与pGEM-T-Easy Vector(购自Promega)以摩尔数3:1的比例加入到反应缓冲液中,充分混匀,4℃过夜连接。将连接产物转化于大肠杆菌DH-5α,筛选阳性克隆,阳性质粒送至南京金斯瑞南京金斯瑞生物科技有限公司测序,测序结果与GenBank序列进行同源性比对分析,与参考序列一致,质粒命名为pGT_up_erm_dowm。
(1)质粒pPHU281_up_erm_down的构建及鉴定
质粒pGT_up_erm_dowm和pPHU281(Hübner,P.,B.Masepohl,W.Klipp,et al..nif geneexpression studies in Rhodobacter capsulatus:ntrC-independent repression by high ammoniumconcentrations.Mol.Microbiol.1993,10:123–132)同时用限制性内切酶EcoRⅠ酶切,将获得的目的片段up_erm_down连接到线性化的pPHU281载体上,转化连接产物于大肠杆菌DH-5α,用红霉素抗性LB平板培养基(含有300μg/ml红霉素)筛选阳性克隆,阳性质粒经EcoRⅠ和SacⅠ酶切后电泳鉴定,结果如图2(C)所示。经测序,与GeneBank中序列进行同源性分析,与参考序列一致。该阳性质粒命名为pPHU281_up_erm_down。
2.P.gRgpA基因敲除突变菌的构建
(1)供体DNA片段的大量制备和纯化
兼顾Pfu酶的扩增效率和细菌同源重组对同源臂长度的要求,我们以upF’(SEQ ID NO:10)和downR’(SEQ ID NO:11)为引物,以质粒pPHU281_up_erm_down为模板,采用ThermoScientific Pfu DNApolymerase(高保真酶,USA),PCR扩增获得同源重组片段A第316位至3996位的核苷酸,得到3.7kb的同源重组片段B。酚-氯仿抽提法纯化同源重组片段B。真空干燥,溶于适量的ddH2O,作为电转化的供体片段。
其中,upF’序列(SEQ ID NO:10):GTGTGGCGCATCAGATATATTTTCATC,downR’序列(SEQ IDNO:11)GGACAAGCCTATGGGTCGAGGACATAAG。
(2)供体DNA片段的电转化:将平板上P.g接种于10ml TSB液体培养基(购自Oxoid,UK)中,厌氧环境下37℃过夜培养。取过夜培养的菌液加入到新鲜配制的100ml TSB液体培养基中,调整OD550至0.1,继续培养至OD550达0.55-0.65。将菌体培养液在4℃、3000g条件下离心10min,弃上清,在菌沉淀中加入100ml电穿孔缓冲液EP buffer(含有质量百分浓度为10%的甘油和1mM MgCl2的水溶液,过滤除菌,4℃预冷),洗涤,离心后,50ml EP buffer重复洗涤,采用常规方法制备感受态细胞,最后采用1ml的EP buffer重悬感受态细胞沉淀。将100ul感受态细胞悬液和2μg供体DNA片段共同加入到一个无菌电击杯中,电击参数为:电压2.5kV、电击时间5ms(ms为毫秒),电击后立即将电击杯中悬液加入到1.0ml预保温的TSB液体培养基中,厌氧环境下37℃培养16h,取300ul菌液接种于添加有红霉素(10μg/ml)的哥伦比亚血琼脂平板。哥伦比亚血琼脂平板的配制方法如下:取哥伦比亚血琼脂(OXOID,UK)38g,氯化血红素(阿拉丁,上海)5mg,脱纤维羊血50mL,维生素K 0.5mg,加入1000mL水,灭菌后得到。
(3)突变株的筛选和鉴定
转化菌在厌氧环境下培养7d后,添加有红霉素的哥伦比亚血琼脂平板上可见黑色、半球形菌落生长(如图3),选取单菌落划板增菌,提取细菌基因组DNA。以引物upF’(序列同上)和ermR(序列同上)扩增含有erm基因的部分重组片段进行正向验证;以RgpAF(SEQID NO:12)和RgpAR(SEQ ID NO:13)为引物特异性扩增RgpA基因编码区长度为1.6kb的一段序列,进行反向验证。1.0%琼脂糖凝胶电泳检测目标片段。
其中,正向验证的反应体系(试剂购自takara)如下:
正向验证的反应条件如下:94℃5min;94℃30s,57℃30s,72℃3min,30cylce;72℃10min。PCR扩增结果如图2(D),产物片段长度约3kb,以质粒pPHU281_up_erm_down为模板作为阳性对照组,同样获得长度约3kb的产物;以P.gATCC33277的基因组DNA为模板作为阴性对照组,未见特异性扩增条带。
反向验证:RgpAF序列(SEQ ID NO:12):TCCACTCAGCAATCGGTGAC,RgpA R序列(SEQ ID NO:13):CGAGCATCTTCTCACCATCC。
反向验证PCR体系如下:
反向验证PCR反应条件:94℃5min;94℃30s,57℃30s,72℃2min,30cylce;72℃10min。
以RgpAF和RgpAR对突变株和野生株基因组DNA进行反向验证,如图2(E)阴性对照野生菌扩增出目的产物,而以突变株和质粒pPHU281_up_erm_down为模板,未见特异性扩增条带,表明在抗性培养基上长出的菌落为RgpA基因敲除突变株。
采用相同方法将pPHU281_up_erm_down转化入P.g,筛选过程中出现较多假阳性,即在含有红霉素的哥伦比亚血琼脂平板上生长的菌落有一部分是未发生基因重组的,从而降低了突变菌的筛选效率。与转化质粒pPHU281_up_erm_down相比,转化片段up_erm_down的优势在于(1)片段的分子质量小,电击过程更易透过细菌感受态细胞的细胞膜进入胞质,转化效率高;(2)在含有红霉素的哥伦比亚血琼脂平板上生长的菌落几乎均为突变菌,筛选效率高;(3)不存在回复突变株,稳定性好。
SEQUENCE LISTING
<110> 南京大学
<120> 牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法
<130> 20150624
<160> 13
<170> PatentIn version 3.3
<210> 1
<211> 816
<212> DNA
<213> P.g
<400> 1
gtgtggcgca tcagatatat tttcatcagt ggattattag ggtatcggtc agaaaaagcc 60
ttccgaatcc gacaaagata gtagaaagag agtgcatctg aaaacagatc attcgaggat 120
tatcgatcaa ctgaaaaggc aggagttgtt ttgcgttttg gttcggaaaa ttacctgatc 180
agcattcgta aaaacgtggc gcgagaattt tttcgttttg gcgcgagaat taaaaatttt 240
tggaaccaca gcgaaaaaaa tctcgcgccg ttttctcagg atttacagac cacaatccga 300
gcattttcgg ttcgtaattc atcgaagaga caggttttac cgcattgaaa tcagagagag 360
aatatccgta gtccaacggt tcatccttat atcagaggtt aaaagatatg gtacgctcat 420
cgaggagctg attggcttag taggtgagac tttcttaaga gacctatcgg cacctacagg 480
aagttcatgg cacacaaggc aaaggaggca atcttcgcag accggactca tatcaaaagg 540
atgaaacgac ttttccatac gacaaccaaa tagccgtcta cggtagacga atgcaaaccc 600
aatatgaggc catcaatcaa tccgaatgac agcttttggg caatatatta tgcatatttt 660
gattcgcgtt taaaggaaaa gtgcatatat ttgcgattgt ggtatttctt tcggtttcta 720
tgtgaatttt gtctcccaag aagactttat aatgcataaa tacagaaggg gtactacaca 780
gtaaaatcat attctaattt catcaaaatg aaaaac 816
<210> 2
<211> 686
<212> DNA
<213> P.g
<400> 2
ttctgtcttg gactcggaga ctttgtgcag acacttttaa tataggtctg taattgtctc 60
agagtatgaa tcgatcgccc gacctccttt taaggaagtc gggcgacttc gtttttatgc 120
ctattattct aatatacttc tgaaacaatt tgttccaaaa agttgcatga aaagattatc 180
ttactatctt tgcactgcaa aaggggagtt tcctaaggtt ttccccggag tagtacggta 240
ataacggtgt ggtagttcag ctggttagaa tacctgcctg tcacgcaggg ggtcgcgggt 300
tcgagtcccg tccataccgc taaaataagg agttgtgttg aaatagtttt tcggcacagc 360
tccatttttg tatgttatcg cagcaccgga aagtataatt gccggatgag attattcaat 420
atgctcggaa gattttctta gaacgaagca gaagtgtttg tctttattac gatctgcttg 480
ggacataggg attaaattag tattattgca ggagggacgg tacatggagt cgcccggcca 540
atcagatgaa gaaagaagaa ctacgattga tttttatggg aacggccgat tttgctgttc 600
cggcactccg agctttggtc gaaaacggat accaagtaaa agctgtggtc actatgccgg 660
acaagcctat gggtcgagga cataag 686
<210> 3
<211> 44
<212> DNA
<213> ARTIFICIAL
<220>
<223> upF
<400> 3
ccgaattcgg atacgggttc gtctatgtag cggcggaaaa atgc 44
<210> 4
<211> 36
<212> DNA
<213> ARTIFICIAL
<220>
<223> upR
<400> 4
cggaagctat cgggggtacc gtttttcatt ttgatg 36
<210> 5
<211> 36
<212> DNA
<213> ARTIFICIAL
<220>
<223> ermF
<400> 5
catcaaaatg aaaaacggta cccccgatag cttccg 36
<210> 6
<211> 36
<212> DNA
<213> ARTIFICIAL
<220>
<223> ermR
<400> 6
ctccgagtcc aagacagaac tgcaggtcga ctctag 36
<210> 7
<211> 36
<212> DNA
<213> ARTIFICIAL
<220>
<223> downF
<400> 7
ctagagtcga cctgcagttc tgtcttggac tcggag 36
<210> 8
<211> 44
<212> DNA
<213> ARTIFICIAL
<220>
<223> down R
<400> 8
aaggatccta tctatctcat gccggaggcg gaaggtggta actc 44
<210> 9
<211> 4305
<212> DNA
<213> ARTIFICIAL
<220>
<223> 重组片段A
<400> 9
ccgaattcgg atacgggttc gtctatgtag cggcggaaaa atgcttctat gtctgtcgtg 60
tccagaattt cttcccaggg tttgccttcc cagtcgccga agttcatctc cttcagccgg 120
tcgtctcgga tggcatcggg atagccgcaa aaggccgcca acttggccgc acgctgcaga 180
gggctggtaa agaccgcctc gggatcgagg cctttgagac gggcacaagc cgccgcagcc 240
tcctcttcga aggtgtctcg aacgtccaca tcggtgaatc cgtagcagtg ctcattgcca 300
ttgagcagca ccgaggtgtg gcgcatcaga tatattttca tcagtggatt attagggtat 360
cggtcagaaa aagccttccg aatccgacaa agatagtaga aagagagtgc atctgaaaac 420
agatcattcg aggattatcg atcaactgaa aaggcaggag ttgttttgcg ttttggttcg 480
gaaaattacc tgatcagcat tcgtaaaaac gtggcgcgag aattttttcg ttttggcgcg 540
agaattaaaa atttttggaa ccacagcgaa aaaaatctcg cgccgttttc tcaggattta 600
cagaccacaa tccgagcatt ttcggttcgt aattcatcga agagacaggt tttaccgcat 660
tgaaatcaga gagagaatat ccgtagtcca acggttcatc cttatatcag aggttaaaag 720
atatggtacg ctcatcgagg agctgattgg cttagtaggt gagactttct taagagacct 780
atcggcacct acaggaagtt catggcacac aaggcaaagg aggcaatctt cgcagaccgg 840
actcatatca aaaggatgaa acgacttttc catacgacaa ccaaatagcc gtctacggta 900
gacgaatgca aacccaatat gaggccatca atcaatccga atgacagctt ttgggcaata 960
tattatgcat attttgattc gcgtttaaag gaaaagtgca tatatttgcg attgtggtat 1020
ttctttcggt ttctatgtga attttgtctc ccaagaagac tttataatgc ataaatacag 1080
aaggggtact acacagtaaa atcatattct aatttcatca aaatgaaaaa cggtaccccc 1140
gatagcttcc gctattgctt ttttgctcat cggtatttgc aacatcatag aaattgcata 1200
cctttgttcc tcggttatat gtttgctcat ctgcaacttt tttttctttg gacggacaat 1260
taaagcaaag atagcaaact ttatccattc agagtgagag aaagggggac attgtctctc 1320
tttcctctct gaaaaataaa tgtttttatt gcttattatc cgcacccaaa aagttgcatt 1380
tataagttga actcaagaag tattcacctg taagaagtta ctaatgacaa aaaagaaatt 1440
gcccgttcgt tttacgggtc agcactttac tattgataaa gtgctaataa aagatgcaat 1500
aagacaagca aatataagta atcaggatac ggttttagat attggggcag gcaaggggtt 1560
tcttactgtt catttattaa aaatcgccaa caatgttgtt gctattgaaa acgacacagc 1620
tttggttgaa catttacgaa aattattttc tgatgcccga aatgttcaag ttgtcggttg 1680
tgattttagg aattttgcag ttccgaaatt tcctttcaaa gtggtgtcaa atattcctta 1740
tggcattact tccgatattt tcaaaatcct gatgtttgag agtcttggaa attttctggg 1800
aggttccatt gtccttcaat tagaacctac acaaaagtta ttttcgagga agctttacaa 1860
tccatatacc gttttctatc atactttttt tgatttgaaa cttgtctatg aggtaggtcc 1920
tgaaagtttc ttgccaccgc caactgtcaa atcagccctg ttaaacatta aaagaaaaca 1980
cttatttttt gattttaagt ttaaagccaa atacttagca tttatttcct gtctgttaga 2040
gaaacctgat ttatctgtaa aaacagcttt aaagtcgatt ttcaggaaaa gtcaggtcag 2100
gtcaatttcg gaaaaattcg gtttaaacct taatgctcaa attgtttgtt tgtctccaag 2160
tcaatggtta aactgttttt tggaaatgct ggaagttgtc cctgaaaaat ttcatccttc 2220
gtagttcaaa gtcgggtggt tgtcaagatg atttttttgg tttggtgtcg tcttttttta 2280
agctgccgca taacggctgg caaattggcg atggagcgga aacgtaaaag aagttatgga 2340
aataagactt agaagcaaac ttaagagtgt gttgatagtg cagtatctta aaattttgta 2400
taataggaat tgaagttaaa ttagatgcta aaaatttgta attaagaagg agtgattaca 2460
tgaacaaaaa tataaaatat tctcaaaact ttttaacgag tgaaaaagta ctcaaccaaa 2520
taataaaaca attgaattta aaagaaaccg ataccgttta cgaaattgga acaggtaaag 2580
ggcatttaac gacgaaactg gctaaaataa gtaaacaggt aacgtctatt gaattagaca 2640
gtcatctatt caacttatcg tcagaaaaat taaaactgaa tactcgtgtc actttaattc 2700
accaagatat tctacagttt caattcccta acaaacagag gtataaaatt gttgggagta 2760
ttccttacca tttaagcaca caaattatta aaaaagtggt ttttgaaagc catgcgtctg 2820
acatctatct gattgttgaa gaaggattct acaagcgtac cttggatatt caccgaacac 2880
tagggttgct cttgcacact caagtctcga ttcagcaatt gcttaagctg ccagcggaat 2940
gctttcatcc taaaccaaaa gtaaacagtg tcttaataaa acttacccgc cataccacag 3000
atgttccaga taaatattgg aagctatata cgtactttgt ttcaaaatgg gtcaatcgag 3060
aatatcgtca actgtttact aaaaatcagt ttcatcaagc aatgaaacac gccaaagtaa 3120
acaatttaag taccgttact tatgagcaag tattgtctat ttttaatagt tatctattat 3180
ttaacgggag gaaataattc tatgagtcgc ttttgtaaat ttggaaagtt acacgttact 3240
aaagggaatg tagataaatt attaggtata ctactgacag cttcggggat cctctagagt 3300
cgacctgcag ttctgtcttg gactcggaga ctttgtgcag acacttttaa tataggtctg 3360
taattgtctc agagtatgaa tcgatcgccc gacctccttt taaggaagtc gggcgacttc 3420
gtttttatgc ctattattct aatatacttc tgaaacaatt tgttccaaaa agttgcatga 3480
aaagattatc ttactatctt tgcactgcaa aaggggagtt tcctaaggtt ttccccggag 3540
tagtacggta ataacggtgt ggtagttcag ctggttagaa tacctgcctg tcacgcaggg 3600
ggtcgcgggt tcgagtcccg tccataccgc taaaataagg agttgtgttg aaatagtttt 3660
tcggcacagc tccatttttg tatgttatcg cagcaccgga aagtataatt gccggatgag 3720
attattcaat atgctcggaa gattttctta gaacgaagca gaagtgtttg tctttattac 3780
gatctgcttg ggacataggg attaaattag tattattgca ggagggacgg tacatggagt 3840
cgcccggcca atcagatgaa gaaagaagaa ctacgattga tttttatggg aacggccgat 3900
tttgctgttc cggcactccg agctttggtc gaaaacggat accaagtaaa agctgtggtc 3960
actatgccgg acaagcctat gggtcgagga cataaggtaa gtcccagtat ggtcaaacta 4020
tacgcacagg aattgggtct gcctattctc cagccggaca atctgaacga ggaatctttt 4080
ctcgatgaac tacggactta tcagccgcac ttgcaaatcg tagtggcttt ccgtatgctt 4140
cctcgctccg tatggcaaat gccccccatg ggaacaatca atctgcatgg ctctctgctg 4200
cccatgtatc gaggagcagc ccctatcaac cacgcgatac gccatggcga tacggaaacg 4260
ggagttacca ccttccgcct ccggcatgag atagatagga tccaa 4305
<210> 10
<211> 27
<212> DNA
<213> ARTIFICIAL
<220>
<223> upF’
<400> 10
gtgtggcgca tcagatatat tttcatc 27
<210> 11
<211> 28
<212> DNA
<213> ARTIFICIAL
<220>
<223> downR’
<400> 11
ggacaagcct atgggtcgag gacataag 28
<210> 12
<211> 20
<212> DNA
<213> ARTIFICIAL
<220>
<223> RgpA F
<400> 12
tccactcagc aatcggtgac 20
<210> 13
<211> 20
<212> DNA
<213> ARTIFICIAL
<220>
<223> RgpA R
<400> 13
cgagcatctt ctcaccatcc 20
Claims (4)
1.牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,其特征在于包括如下步骤:
(1)扩增牙龈卟啉单胞菌RgpA基因的上、下游同源臂;
(2)扩增红霉素抗性基因片段;
(3)构建两端为所述RgpA基因的上、下游同源臂,中间为红霉素抗性基因片段的同源重组片段;
(4)将同源重组片段转化入牙龈卟啉单胞菌内,进行同源重组,采用红霉素抗性平板筛选,获得牙龈卟啉单胞菌RgpA基因敲除突变株。
2.根据权利要求1所述牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,其特征在于所述上游同源臂的序列如SEQ ID NO:1所示,所述下游同源臂的序列如SEQ ID NO:2所示。
3.根据权利要求1或2所述牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,其特征在于步骤(4)中采用电转化方法将同源重组片段转化入牙龈卟啉单胞菌内,电击条件为:电压为2.5kV、电击时间为5ms。
4.根据权利要求3所述牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法,其特征在于以牙龈卟啉单胞菌的基因组DNA为模板,以upF和upR为引物,扩增RgpA基因的上游同源臂;以牙龈卟啉单胞菌的基因组DNA为模板,以downF和downR为引物,扩增RgpA基因的下游同源臂;所述upF的序列如SEQ ID NO:3所示,所述upR的序列如SEQ ID NO:4所示;所述downF的序列如SEQ ID NO:7所示,所述downR的序列如SEQ ID NO:8所示。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510358543.5A CN104962575B (zh) | 2015-06-25 | 2015-06-25 | 牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510358543.5A CN104962575B (zh) | 2015-06-25 | 2015-06-25 | 牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104962575A true CN104962575A (zh) | 2015-10-07 |
CN104962575B CN104962575B (zh) | 2018-09-07 |
Family
ID=54216665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510358543.5A Expired - Fee Related CN104962575B (zh) | 2015-06-25 | 2015-06-25 | 牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104962575B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117305336A (zh) * | 2023-08-16 | 2023-12-29 | 杭州师范大学 | 一种靶向脑膜炎败血伊丽莎白菌的结合转移型的基因编辑系统及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101942410A (zh) * | 2010-06-13 | 2011-01-12 | 浙江大学 | 牙龈卟啉单胞菌促血凝功能结构域hgp44基因的克隆重组菌及构建方法 |
WO2013063656A1 (en) * | 2011-11-04 | 2013-05-10 | Oral Health Australia Pty Ltd | Gingipain inhibitory propeptides |
-
2015
- 2015-06-25 CN CN201510358543.5A patent/CN104962575B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101942410A (zh) * | 2010-06-13 | 2011-01-12 | 浙江大学 | 牙龈卟啉单胞菌促血凝功能结构域hgp44基因的克隆重组菌及构建方法 |
WO2013063656A1 (en) * | 2011-11-04 | 2013-05-10 | Oral Health Australia Pty Ltd | Gingipain inhibitory propeptides |
Non-Patent Citations (6)
Title |
---|
M. A. CURTIS,ET AL.: "Characterization of an Adherence and Antigenic Determinant of the ArgI Protease of Porphyromonas gingivalis Which Is Present on Multiple Gene Products", 《INFECTION AND IMMUNITY》 * |
MASAYUKI TOKUDA,ET AL.: "Role of Arg-Gingipain A in Virulence of Porphyromonas gingivalis", 《INFECTION AND IMMUNITY》 * |
刘标: "《抗虫转基因植物环境风险评价和监测》", 31 December 2014 * |
李昌瑜等: "同源重组法敲除酵母snoRNA基因的初步探讨", 《湖北大学学报》 * |
李琛,等: "牙龈卟啉单胞菌W83 PG0352基因突变株构建及鉴定研究", 《中国实用口腔科杂志》 * |
杨巍华,等: "牙龈卟啉单胞菌类胰蛋白酶基因调控和表达", 《牙体牙髓牙周病学杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117305336A (zh) * | 2023-08-16 | 2023-12-29 | 杭州师范大学 | 一种靶向脑膜炎败血伊丽莎白菌的结合转移型的基因编辑系统及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104962575B (zh) | 2018-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111849979B (zh) | 一种靶向敲除RPSA基因的sgRNA及RPSA基因敲除细胞系的构建方法 | |
CN102392080B (zh) | 一种鉴定番茄黄化曲叶病毒抗性的方法 | |
CN112522300A (zh) | 一种培育广谱抗细菌性条斑病水稻的方法及引物和表达盒 | |
CN110862951B (zh) | 一种维氏气单胞菌减毒菌株的构建方法、菌株及其应用 | |
CN102776220B (zh) | 布鲁氏菌病a19分子标记疫苗株的构建及毒力和免疫原性的测定 | |
CN102154313B (zh) | 棉花原花色素合成调控基因GhPAPMYB1及其应用 | |
CN109234221B (zh) | 一种马铃薯x病毒弱毒疫苗及其制备方法与应用 | |
CN104962575A (zh) | 牙龈卟啉单胞菌RgpA基因敲除突变株的制备方法 | |
CN102732456B (zh) | 耐有机溶剂糖苷酶Fru6及其突变体和应用 | |
CN103834605B (zh) | 一种阿维菌素产生菌及其制备方法和应用 | |
CN102161974A (zh) | 哈维氏弧菌外膜蛋白ompK抗原的制备方法、应用以及表达该抗原的菌株 | |
CN102533628B (zh) | 一株枯草芽孢杆菌工程菌及其在生产肝素酶ⅰ中的应用 | |
CN106754592B (zh) | 猪链球菌2型Rex基因敲除突变株SS2-1ΔRex及其构建方法和应用 | |
CN104694432B (zh) | 缺失phoQ和rpoS基因的都柏林沙门氏菌及应用 | |
CN103305544B (zh) | 阿卡波糖工程菌及其制备方法和应用 | |
CN103421732B (zh) | 表达副猪嗜血杆菌表面抗原的猪霍乱沙门氏菌减毒疫苗 | |
CN101153284A (zh) | 羊型布鲁氏杆菌m5菌株核糖体蛋白l7/l12的基因、其编码蛋白及应用 | |
CN105039203A (zh) | 一种鸭疫里氏杆菌基因缺失株及其应用 | |
CN105624078B (zh) | 一株减毒猪霍乱沙门氏菌及其制备方法和应用 | |
CN1128880C (zh) | 蓝藻转基因表达系统及其用于表达胸腺素α1的方法 | |
CN110317820B (zh) | 一种α-半乳糖苷酶LrgalA基因 | |
CN102206666B (zh) | 一种质粒载体pLGF及其应用 | |
CN102796679B (zh) | 血清5型猪胸膜肺炎放线杆菌Apx I C/Apx II C双基因缺失疫苗候选株 | |
Bové | Spiroplasma citri: fifteen years of research | |
CN112481183A (zh) | 一种减毒鰤鱼诺卡氏菌及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151223 Address after: 210012, No. 30, Central Road, Xuanwu District, Jiangsu, Nanjing Applicant after: Nanjing City stomatology Hospital Address before: 210012 Nanjing University, 22 Hankou Road, Jiangsu, Nanjing Applicant before: Nanjing University |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180907 Termination date: 20210625 |
|
CF01 | Termination of patent right due to non-payment of annual fee |